Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Marimed (MRMD) over the last 13 years, with Q3 2025 value amounting to $145.5 million.

  • Marimed's Non-Current Assets fell 672.75% to $145.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $596.2 million, marking a year-over-year decrease of 105.91%. This contributed to the annual value of $153.5 million for FY2024, which is 607.43% up from last year.
  • Per Marimed's latest filing, its Non-Current Assets stood at $145.5 million for Q3 2025, which was down 672.75% from $147.2 million recorded in Q2 2025.
  • Marimed's Non-Current Assets' 5-year high stood at $156.0 million during Q3 2024, with a 5-year trough of $58.3 million in Q1 2021.
  • Its 5-year average for Non-Current Assets is $119.0 million, with a median of $131.5 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 6213.2% in 2022, then plummeted by 672.75% in 2025.
  • Quarter analysis of 5 years shows Marimed's Non-Current Assets stood at $78.6 million in 2021, then surged by 37.49% to $108.1 million in 2022, then skyrocketed by 33.9% to $144.7 million in 2023, then grew by 6.07% to $153.5 million in 2024, then decreased by 5.2% to $145.5 million in 2025.
  • Its Non-Current Assets stands at $145.5 million for Q3 2025, versus $147.2 million for Q2 2025 and $150.0 million for Q1 2025.